[ LE TRASTUZUMAB (HERCEPTIN*) dans le traitement du cancer du sein: Revue de la littérature ]
Volume 18, Issue 1, September 2015, Pages 95–98
Youssef Benabdejlil1, Khalid Guelzim2, Ihssane Hakimi3, Jaouad Kouach4, Driss Moussaoui5, and Mohammed Dehayni6
1 Department of Gynecology-Obstetric, Military Training Hospital Med V, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco
2 Faculté de Médecine et de Pharmacie, Université Mohamed V, Rabat, Morocco
3 Service de Gynécologie Obstétrique, Hôpital Militaire d'Instruction Mohamed V, Rabat, Morocco
4 Faculté de Médecine et de Pharmacie, Université Mohamed V, Rabat, Morocco
5 Department of Gynecology-Obstetric, Military Training Hospital Med V, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco
6 Department of Gynecology-Obstetric, Military Training Hospital Med V, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco
Original language: French
Copyright © 2015 ISSR Journals. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Trastuzumab is the first target molecule designed for breast cancer treatment. In first-line metastatic, trastuzumab in combination with chemotherapy significantly improved survival of patients bearing HER2-positive breast cancer. In adjuvant trastuzumab was tested in several randomized trials. In contemporary literature, many strong arguments confirm the clear survival benefit of trastuzumab in adjuvant administered concomitantly with taxane-based chemotherapy and concomitant with radiation therapy, and for a period of one year.
Author Keywords: breast, cancer, trastuzumab, HER, chemotherapy.
Volume 18, Issue 1, September 2015, Pages 95–98
Youssef Benabdejlil1, Khalid Guelzim2, Ihssane Hakimi3, Jaouad Kouach4, Driss Moussaoui5, and Mohammed Dehayni6
1 Department of Gynecology-Obstetric, Military Training Hospital Med V, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco
2 Faculté de Médecine et de Pharmacie, Université Mohamed V, Rabat, Morocco
3 Service de Gynécologie Obstétrique, Hôpital Militaire d'Instruction Mohamed V, Rabat, Morocco
4 Faculté de Médecine et de Pharmacie, Université Mohamed V, Rabat, Morocco
5 Department of Gynecology-Obstetric, Military Training Hospital Med V, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco
6 Department of Gynecology-Obstetric, Military Training Hospital Med V, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco
Original language: French
Copyright © 2015 ISSR Journals. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Trastuzumab is the first target molecule designed for breast cancer treatment. In first-line metastatic, trastuzumab in combination with chemotherapy significantly improved survival of patients bearing HER2-positive breast cancer. In adjuvant trastuzumab was tested in several randomized trials. In contemporary literature, many strong arguments confirm the clear survival benefit of trastuzumab in adjuvant administered concomitantly with taxane-based chemotherapy and concomitant with radiation therapy, and for a period of one year.
Author Keywords: breast, cancer, trastuzumab, HER, chemotherapy.
Abstract: (french)
Le trastuzumab est la première molécule ciblée conçue pour le traitement du cancer du sein. En première ligne métastatique, le trastuzumab en association avec la chimiothérapie a amélioré significativement la survie des patientes porteuses d'un cancer du sein HER2-positif. En adjuvant, le trastuzumab a été testé dans plusieurs essais randomisés. Dans la littérature médicale contemporaine, plusieurs arguments forts confirment le bénéfice clair en survie du trastuzumab en adjuvant, administré en concomitant avec une chimiothérapie à base de taxanes et en concomitant avec la radiothérapie, et pendant une durée d'une année.
Author Keywords: cancer, sein, trastuzumab, HER, chimiothérapie.
How to Cite this Article
Youssef Benabdejlil, Khalid Guelzim, Ihssane Hakimi, Jaouad Kouach, Driss Moussaoui, and Mohammed Dehayni, “Trastuzumab in early breast cancer: Literature Review,” International Journal of Innovation and Scientific Research, vol. 18, no. 1, pp. 95–98, September 2015.
